Summary Ki-ras activation by point mutation on codon 12 has been reported in non-small-cell lung carcinomas and in various models of experimental lung tumours induced by chemical carcinogens. The cellular targets for carcinogenic compounds of tobacco smoke are usually considered to be the cells of the bronchial mucosa or alveolar epithelium. However, little is known about preneoplastic events in bronchopulmonary carcinogenesis. The hypothesis of the presence of widespread target cells containing Ki-ras mutation was investigated by evaluating concurrent neoplastic and non-neoplastic bronchial and alveolar samples from 51 patients with non-small-cell lung carcinomas. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method used can detect one cell with a mutation on codon 12 among 102 normal cells. In tumour samples, a mutation was detected in 20% of adenocarcinomas, but in none of the adenosquamous or squamous cell carcinomas. No mutation was detected in the non-neoplastic bronchial or parenchymal samples. When using an enriched PCR-RFLP method detecting one mutated allele among 103 normal alleles a mutation was detected in 23% of adenocarcinomas. In conclusion, Ki-ras activation by mutation on codon 12 was not observed in non-neoplastic bronchial or parenchymal tissues in patients with bronchopulmonary cancers and does not appear to be a genetic event present in non-malignant epithelial target cells exposed to tobacco smoke.
The Ki-ras proto-oncogene has been shown to be activated by point mutations in a wide variety of human and experimental carcinomas (Barbacid, 1987; Bos, 1989) . Dutch researchers reported that in lung carcinomas Ki-ras mutations were found exclusively in adenocarcinomas With a frequency of 30% in smokers and 5% in non-smokers (Bos, 1989; Slebos et al., 1991) . In neoplastic tissues more than 90% of Ki-ras mutations occurred in codon 12 (Bos, 1989; Slebos et al., 1991) . In contrast, in another series from Spain, Ki-ras mutations were not only detected in adenocarcinomas, but the majority of Kiras mutations were present in squamous cell carcinomas (Rosell et al., 1993) . In experimental models of lung tumours conducted in different mouse strains, various chemical carcinogens have been demonstrated to induce tumours harbouring a Ki-ras mutation restricted to codon 12 [You et al., 1989 [You et al., , 1993 Mass et al., 1993) . These human and experimental data suggest that codon 12 of Ki-ras may be a specific target for the mutagenic activity of various compounds of tobacco smoke (HusafvelPursiaisen et al., 1993) .
In colonic carcinogenesis, Ki-ras mutation has been shown to be a preneoplastic event (Burmer and Loeb, 1989) . In contrast, little is known about preneoplastic events in bronchopulmonary carcinogenesis. However, recent reports demonstrated that Ki-ras and p53 mutations occur very early in the development of pulmonary adenocarcinomas (Sozzi et al., 1992; Sundaresan et al., 1992; Benett, 1993; Li et al., 1994) . The cellular targets for the carcinogenic compounds of tobacco smoke are usually considered to be either the bronchial mucosa or alveolar epithelium (Carney, 1991) . Therefore, the hypothesis of the presence of widespread target cells containing Ki-ras mutations in the respiratory tract as already shown for the suppressor gene p53 has to be considered (Sozzi et al., 1992; Sundaresan et al., 1992; Benett 1993; Li et al., 1994 Consequently, the present study was designed to investigate the presence of activated Ki-ras by mutation in codon 12 not only in adenocarcinomas, but also in various non-small-cell bronchopulmonary cancer tissues and in neighbouring and distant non-neoplastic bronchial and lung tissues.
Materials and Methods
Tissue specimens Tissue specimens were collected in 68 smokers or ex-smokers who were patients for thoracotomy undertaken with curative intent. The resected material was transported to the pathology department, and after examination by the pathologist, a representative part of the tumour was snapfrozen and stored at -70°C until analysis. To increase the sensitivity of detection, macroscopically neoplastic tissue was collected under a dissection microscope.
Concomitantly, in 51 patients, non-neoplastic bronchial and parenchymal specimens were also collected close to and away from the tumour and snap-frozen at -70°C. Tissue samples were also embedded in paraffin wax for histological analysis and classified according to the WHO classification into squamous cell carcinomas (SCC), adenocarcinomas (AC) or adenosquamous carcinomas (ASC).
DNA evaluation by polymerase chain reaction (PCR) amplification and restriction fragment length polymorphism (RFLP) analysis A rapid method of extraction of DNA from tissues and cell cultures was performed according to Higuchi (1989) . Ki-ras codon 12 sequences were amplified according to Jiang et al.
(1989) using a 5'-end primer that contains a C substitution at the first position of codon 11 creating a BstNI site which overlaps the first two nucleotides of codon 12. The 3' primer also contains a substitution creating a control BstNI site.
The primers, synthesized by a DNA synthesiser (Applied Biosystems) and purified by high performance liquid chromatography (HPLC) (Genset, Paris), were Ki-ras 5': 5'-ACT GAA TAT AAA CTT GTG GTA GTT GGA CCT-3' and Ki-ras 3': 5-TCA AAG AAT GGT CCT GGA CC-3'. DNA was amplified according to Saiki et al. (1988) using a Perkin-Elmer Cetus thermal cycler. DNA was denatured at 94°C for 10 min and subsequently amplified for 40 cycles. The PCR reaction was carried out in 0.1 ml containing 50 mM potassium chloride, 10 mM Tris-HCl, pH 8.3, 1.5 mM magnesium chloride, 2.0 mM of each dNTP, with 350 ng of each primer and 2.5 units of Taq DNA polymerase (Beckman). The reaction mixture was overlayed with mineral oil. Each cycle included a 1 min denaturation step at 94°C, a 1 min annealing step at 55°C and a 1.5 min elongation step at 72°C. PCR reaction product (10 Ml) was analysed by 2% agarose gel electrophoresis. Specimens with negative results were re-evaluated in a second separate PCR amplification. Aliquots (20 ul) of the PCR reaction product were then digested with the restriction enzyme Bst,/it>NI (Boehringer Mannheim, France) at 37°C for 2 h and electrophoresed through an 8% polyacrylamide gel. The results were analysed after ethidium bromide staining and UV transillumination.
Codon 12 mutation identification by specific oligonucleotide hybridisation Ten samples (six wild-type and four mutated codon 12 of c-K-ras genes) were studied by specific oligonucleotide hybridisation. After extraction, the DNA was heat denatured and used for in vitro amplification. The PCR procedure, oligonucleotide sequences, hybridisation conditions in ammonium tetramethylchloride and composition of the seven probes used have been described previously by Verlaan de Vries et al. (1986) .
Enriched PCR/RFLP analysis An enriched PCR/RFLP method derived from Kahn et al. (1991) was concurrently performed in non-tumoral and tumoral samples from lungs of 32 patients with adenocarcinomas. Ki-ras codon 12 sequences were amplified in two steps. Primers used were K-ras 5' (as described above), K-ras 3' wild type (5'-TCA AAG AAT GGT CCT GCA CC-3') and K-ras 3' (as described above).
First step amplification The PCR reaction was carried out in 0.1 ml containing 50 mM potassium chloride, 10 mM TrisHCl, pH 8.3, 1.5 mM magnesium chloride, 0.2 mM dNTPs and 2.5 units of Taq DNA polymerase (Beckman). Primer concentrations were 10 ng each of K-ras 5' and Ki-ras 3' wild-type. The reaction mixture was overlayed with mineral oil. Each cycle included a 1 min denaturation step at 940C, a 1 min 30 s annealing step at 56°C and a 2 min elongation step at 72°C, for a total of 15 cycles.
Intermediate digestion Aliquots (5 jul) of the first PCR reaction were digested with 20 units of the restriction enzyme BstNI (Boehringer Mannheim, France) in a final volume of 10 pl at 37°C for 3 h under conditions recommended by the supplier.
Second step amplification Digested mixture (10 pl) was used in the second amplification step. These aliquots were diluted to a final volume of 50 Figure 1 . Therefore, the presence of a 143 bp fragment after digestion is the hallmark of the presence of mutated Ki-ras genes on codon 12.
Detection of codon 12 c-Ki-ras mutation in SW480 and HT29 cell lines Two human cell lines with documented codon 12 Ki-ras gene were examined to validate the method. SW480 is derived from a human colon carcinoma and is a homozygous mutant (GGT to GTT) (Capon et al., 1983) . HT29 is also derived from a human colon carcinoma and has homozygous wildtype alleles (codon 12 Ki-ras, GGT). PCR amplification and BstNI RFLP analysis of DNA from the SW 480 cell line showed only a 143 bp fragment confirming the homozygous mutation. Analysis of DNA from the HT29 cell line showed a wild-type 114 bp fragment. Analysis of a mixture of DNA from the two cell lines showed two fragments of 143 and 114 bp respectively. The sensitivity of the assay was therefore tested by a series of titration experiments. The threshold of detection was one cell with a homozygous mutation in the midst of 102 cells with a wild-type Ki-ras gene (Figure 2 ) (Urban et al., 1993) . Tables I  and II. When using the one step PCR-RFLP method no mutation involving the codon 12 of Ki-ras gene was detected in the 20 squamous cell and four adenosquamous cell carcinomas. In contrast a mutation was detected in 9/44 (20.5%) of the adenocarcinomas. When using the enriched PCR-RFLP method, a mutation was detected in 10/44 (23%) of the adenocarcinomas.
As a control of the method, ten samples were studied by specific oligonucleotide hybridisation. No mutation was detected in the six samples found to be of the wild type by PCR-RFLP analysis. In contrast, the four samples in which a mutated codon 12 of Ki-ras was detected by PCR-RFLP analysis, the mutation could be specific (2:GGT-+GTT; 1 :GGT-+GCT; 1 :GGT-+TGT).
No mutation of the codon 12 of Ki-ras gene was detected in the non-neoplastic bronchial and parenchymal specimens even in the samples from lungs with adenocarcinomas harbouring a Ki-ras mutation (Table II) . Non-neoplastic 0 0 tissuea aApparently normal bronchial and lung tissue. Discussion
The methods chosen for the detection of a mutation in codon 12 of the Ki-ras gene were a combination of PCR amplification of DNA and RFLP analysis (Jiang et al., 1989) . These methods offer several advantages. They are highly specific, as the loss of the restriction site at the target is diagnostic for the presence of a mutation. An additional restriction site offers a control of the restriction enzyme digestion. In the present study the one-step PCR -RFLP analysis was shown to be able to detect a K-ras mutation when it is present in 1% of cells studied. When using the enriched PCR-RFLP procedure, one mutated allele could be detected among 103 normal alleles.
In the present series of 68 non-small-cell lung carcinomas, activation of Ki-ras by a mutation on codon 12 In experimental models of lung tumours induced in various murine strains, the presence of Ki-ras mutation is a particularly reproducible event. For example, in the strain A mouse highly susceptible to spontaneous and inducible lung tumours, Ki-ras point mutations in spontaneous lung tumours were found in both codons 12 (60%) and 61 (30%) (You et al., 1989 (You et al., , 1993 Mass et al., 1993) . After tumour induction in this mouse strain, the pattern of Ki-ras mutation was different according to the carcinogen used: in codon 12 for 100% of tumours after induction by methyl nitrosourea and 93% after benzo[a]pyrene exposure, in contrast, 90% of the mutations after ethyl carbonate exposure were situated in codon 61 (You et al., 1989) . Benzo [a] pyrene is considered to be a major carcinogenic compound of tobacco smoke (Loeb et al., 1984) . In human lung and pancreatic adenocarcinomas, the presence of codon 12 Ki-ras mutation has been shown to be related to tobacco smoke exposure (Hruban et al., 1993; Westra et al., 1993) .
Ras activation by mutation, particularly Ki-ras, has been shown to be present in a wide variety of human neoplasms (Bos, 1989) . Moreover, it has been suggested that Ki-ras oncogene activation could precede the onset of neoplasia (Kumar et al., 1990) . For colonic carcinoma, Ki-ras activation by mutation was observed in adenomas before the development of non-invasive cancer and is therefore under investigation for the survey of at-risk patients (Sidransky et al., 1992) . Moreover, when using an enriched PCR method, Ki-ras mutations could be detected in normal colonic mucosa at a distance from the tumour (Ronai et al., 1994; Minamoto et al., 1995) . For pancreatic carcinomas, Kiras mutations have been detected in mucous hyperplasia associated with pancreatitis, suggesting they may be precancerous epithelial modifications (Yanagisawa et al., 1993) . For lung adenocarcinomas, c-Ki-ras mutations occur early since they have been detected in all stages of lung cancer (Li et al., 1994) . Moreover, these mutations are considered to be an irreversible event (Westra et al., 1993) .
Widespread dysplastic lesions have been observed in bronchi of cigarette smokers increasing in a dose-dependent manner according to the number of cigarettes smoked (Auerbach et al., 1979) . Multiple mutations are necessary for the transformation of epithelial cells and the exact order in which they are acquired is difficult to ascertain. p53 mutations present in both squamous cell carcinomas and adenocarcinomas have been detected in association with lesions considered to be precancerous such as bronchial squamous metaplasia or dysplastic tissue (Sozzi et al. 1992; Sundaresan et al., 1992; Benett, 1993; Li et al., 1994) . Similar results were reported for the loss of 3p allele observed in most bronchopulmonary carcinomas (Brauch et al., 1987) .
In contrast, in our series, as for the patient investigated by Santos et al. (1984) , no Ki-ras mutations in codon 12 were detected in bronchial and lung parenchymal samples from patients with non-small-cell lung carcinomas, even when mutations were present in tumour samples. Moreover, no Kiras mutation was detected in dysplastic bronchial epithelium associated with lung adenocarcinomas (Li et al., 1994 ). However, rare cells with mutations below the threshold of detection may be present. Clements et al. (1995) recently reported Ki-ras mutation in non-malignant bronchial tissue in patients with lung carcinomas. Such a discrepancy can be explained by the fact that Clements et al. evaluated samples from the carina of proximal bronchi. In contrast, we deliberately studied peripheral bronchial or alveolar lung tissue as they are suspected to be possible cellular targets for carcinogens in adenocarcinomas. Bronchial carina has been shown to be the site of epithelial changes in response to constant exposure to airborne contaminants (Knudtson et al., 1960) . However, it is not suspected to be the site of occurrence of adenocarcinomas.
In conclusion, Ki-ras mutations were detected in proximal bronchial carina in another study. In the present study, Kiras mutations were not detected in peripheral bronchial and lung parenchyma associated with lung tumours, particularly adenocarcinomas. These results suggest that these mutations do no occur in widespread cellular genomes induced by tobacco smoke in peripheral bronchial and lung tissue.
